This is a prospective randomized clinical study conducted at Kasr-El-Aini Center of Clinical Oncology and Nuclear Medicine (NEMORK) during the period between November 2006 to May 2010 over sixty female patients with breast cancer were recruited each patient was planned by 3D conformal technique, and randomized to Arm A treatment by 50Gy/25ttt/5ws (200Gy/fraction, five days per week) and Arm B treatment by 42.5Gy/16ttt/3ws (260Gy/fraction, five days per week).The results of this study ensured that no statistically significant differences were reported between the two doses considering locregional recurrence and survival. Further studies are needed to prove the safety and efficacy of hypofractionation with large number of patients and longer follow-up.